Peginterferon Alfa‐2a (40KD) Plus Lamivudine or Entecavir in Children With Immune‐Tolerant Chronic Hepatitis B

Mieli‐Vergani, Giorgina; Bansal, Sanjay; F. Daniel, James; Kansu, Aydan; Kelly, Déirdre; Martín, Carmen; Tizzard, Sarah; Wirth, Stéfan; Q. Zhou, Julian; Vergani, Diego

doi:10.1097/mpg.0000000000003118

Public

Peginterferon Alfa‐2a (40KD) Plus Lamivudine or Entecavir in Children With Immune‐Tolerant Chronic Hepatitis B

Published in Journal of Pediatric Gastroenterology and Nutrition • Mar 3, 2021

Authors:

Giorgina Mieli‐Vergani

Sanjay Bansal

James F. Daniel

Abstract

OBJECTIVE: Treatment guidelines for chronic hepatitis B (CHB) do not recommend antiviral therapy for patients in the immune-tolerant phase of the disease, which generally occurs in children who acquire hepatitis B virus (HBV) vertically and may last for decades. On the basis of promising results of ...

Subject

Medicine

Entecavir

Lamivudine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!